Get the Weekly Intelligence Brief — top committee picks every Sunday.
LQDA · NASDAQ · STOCK

Liquidia Corporation

Healthcare Updated August 11, 2026
$88.09
52W $21.15 – $93.61
68/100
$7.83B
368.3
0.57
AI Committee Verdict
Buy
68/100
Conviction: Contested · 67% agreement · 6 analysts
Contested

Is LQDA Bullish or Bearish?

Bullish. Innellis AI committee rates Liquidia Corporation (LQDA) Buy with a composite score of 68/100 , based on 6 analysts with 67% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +7.01 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -12.99 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull & Bear Case

Bull Case
  • ROE of 46.8% shows genuine earnings power backing the valuation — Value
  • Revenue growing 1936.7% YoY -- genuine top-line momentum — Growth
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • P/E of 362.9 is expensive by classic value standards — Value
  • Price-to-book of 12.9x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
  • Weekly RSI at 81 -- overbought on the larger timeframe too — Technical
  • Bollinger bandwidth of 21.9% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
68/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 7%
of 192 Healthcare peers
Value Analyst neutral
42 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 46.8% shows genuine earnings power backing the valuation
− P/E of 362.9 is expensive by classic value standards
Growth Analyst bullish
85 / 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 1936.7% YoY -- genuine top-line momentum
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst neutral
52 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
− Bollinger bandwidth of 21.9% signals elevated volatility
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst bullish
90 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+1.00 across 1 articles, 14d)
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
55.0
Neutral
MACD Histogram
-0.120
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.66
Inside Bands
Price vs Moving Averages
EMA 9
$88.16 Below
EMA 21
$85.05 Above
EMA 50
$76.88 Above
EMA 200
$52.32 Above

Fundamental Analysis

Valuation
26
Profitability
35
Financial Health
70
Cash Flow
70
Valuation
P/E Ratio 368.3×
P/B Ratio 71.37×
PEG Ratio 1.47
Dividend Yield 0.00%
52W High $93.61
52W Low $21.15
Quality & Growth
ROE -15402.7%
ROA -2101.8%
Gross Margin 9178.4%
Operating Margin 1581.3%
Revenue Growth YoY
Debt / Equity 1.70
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 368.3 (rich relative to a 15-40x range); Price-to-book of 71.4x; PEG ratio of 1.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -154.0%; Return on assets of -21.0%; Net margin of 7.7%; Gross margin of 91.8%; Current ratio of 2.22 (healthy short-term liquidity); Debt-to-equity of 1.70; Free cash flow per share is positive (0.47); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full LQDA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore LQDA Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime